Skip to Main Content
Capabilities /

Generic Drug / ANDA Litigation

Clearing the path for generic options.

Our firm helps manufacturers of generic pharmaceuticals navigate the regulatory thicket of the Food and Drug Administration (FDA) and bring products to market quickly. To advance clients’ business goals, our team develops innovative strategies that include District Court litigation, inter partes reviews (IPR) and work-arounds. Our record of success includes advising clients on bringing to market generic competitors for brand-name drugs such as Ambien CR®, Clarinex®, Cymbalta®, Lidoderm® and Wellbutrin XL®.

Husch Blackwell has one of the premier Abbreviated New Drug Application (ANDA) and generic drug patent litigation practices in the country. Our attorneys have extensive experience at the trial and appellate levels litigating Hatch-Waxman statutory patent infringement and other actions involving prescription drugs. We have been leaders in using inter partes review to challenge the validity of existing patents more quickly and cheaply. In addition, Husch Blackwell is the only law firm that is a member of the Association for Accessible Medicines (AAM), the leading trade association for the generic drug industry.

Related areas of focus:

Testimonial Tina Guilder, CEO, Virtus Pharmaceuticals

“The Husch Blackwell attorneys were fierce and tireless advocates for Virtus. In the face of aggressive actions by our competitors and FDA regulators, they developed and executed a legal plan that protected an important market for us. They have my gratitude and highest recommendation.”

Read how invested partnerships make a difference
Client Results

Husch Blackwell's seasoned team leads clients forward.

See examples from previous projects